Chapter 8: Designing Adaptive Organizations P a g e | 9
boards, and computers are readily available. With no office walls, inviting common areas, and different
departments mixed together in large open spaces, spontaneous communication occurs more often. Studies
show that people whose office cubicles are directly adjacent to main walkways or office atriums report 60
percent more face-to-face communication, while those with informal meeting spaces (such as open
lounges, or team work rooms) within 75 feet of their desks report 102 percent more face-to-face
communication.
At Lilly, CEO John Lechleiter restructured the company to significantly improve communication in
product development teams and speed up the entire drug development process. One of his first steps was
to put everyone involved in the drug development process, from scientists, to government specialists who
work with the Food and Drug Administration, to those who bring finished products to markets, under one
building which Lilly named the Development Center of Excellence. Why do that? To increase the
While Lilly used behavioral informality to increase communication in product development teams, it
reengineered internal processes to significantly increase the speed with which it completed the formal
phases of drug development and testing.
Reengineering is the fundamental rethinking and radical redesign of business processes to achieve
dramatic improvements in performance measures, such as cost, quality, service, and speed. When
reengineering organizations, managers must ask themselves, Why do we do what we do? and Why do
we do it the way we do? The usual answer is Because thats the way weve always done it.
Reengineering is about significant change, about starting over by throwing out the old ways of getting
work done. It is also about processes, that is, how things get done.
According to CEO John Lechleiter, the Development Center of Excellence is implementing a project
management methodology called Critical Chain, developed by physicist Eli Goldratt. Critical Chain was
actually first applied at Lilly in a completely different context by our IT group. They, in turn, helped our
research labs launch a pilot program that has proved the power of Critical Chain in drug development.
Historically, across our pipeline, we have a 60 percent success rate in hitting milestones on time in other
words, we miss almost half of our deadlines. In the Critical Chain pilot program, the success rate so far is
100 percent. Thats why were now applying Critical Chain in force.